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Abstract: Spiders and scorpions are notorious for their fearful dispositions and their ability to inject
venom into prey and predators, causing symptoms such as necrosis, paralysis, and excruciating
pain. Information on venom composition and the toxins present in these species is growing due to
an interest in using bioactive toxins from spiders and scorpions for drug discovery purposes and for
solving crystal structures of membrane-embedded receptors. Additionally, the identification and
isolation of a myriad of spider and scorpion toxins has allowed research within next generation
antivenoms to progress at an increasingly faster pace. In this review, the current knowledge of
spider and scorpion venoms is presented, followed by a discussion of all published biotechnological
efforts within development of spider and scorpion antitoxins based on small molecules, antibodies
and fragments thereof, and next generation immunization strategies. The increasing number of
discovery and development efforts within this field may point towards an upcoming transition from
serum-based antivenoms towards therapeutic solutions based on modern biotechnology.
Keywords: antivenom; spider venom; scorpion venom; antitoxin; venom neutralization; venomics;
antibodies; antivenom design
1. Introduction
Scorpion stings and spider bites are a major public health concern in developing parts of the world,
yet envenomation from these creatures still remains a neglected tropical disease [1]. Scorpionism
affects people in Northern Africa, the Middle East, Central and South America, and to some extent
India [2,3]. In comparison, spider bites mainly affect people in the Americas, Australia, and Africa [4],
although bites are also known to occur in Europe [5]. In the scorpion order, nearly 2000 species are
recognized [3], which is significantly less than the 44,000 recognized spider species [6]. Fortunately,
only a subset of these species are of medical relevance, with the members of the Buthidae family
(including bark scorpions and fat-tailed scorpions), Latrodectus genus (widow spiders) and Loxosceles
genus (recluse spiders) being the main species with venom that may cause harm to humans [6,7].
Scorpions are considered the second most dangerous venomous animals to humans (after snakes),
and their stings mainly affect children and adolescents [6]. Effective treatment against envenomings
from the most venomous scorpions and spiders consists of parental administration of animal-derived
antisera by medically trained personnel. Currently, there are 19 antivenoms for human use and one
Toxins 2016, 8, 226; doi:10.3390/toxins8080226 www.mdpi.com/journal/toxins
Toxins 2016, 8, 226 2 of 33
antivenom for animal use on the market for scorpion stings, whereas only 10 antivenoms are used
clinically for the treatment of spider bites (see Tables 1 and 2, respectively). All of these antivenoms
are of equine origin, and although they are effective in neutralizing scorpion and spider venoms,
such animal-derived antisera suffer from significant drawbacks due to the heterologous nature of
the proteins present in the antisera, which may elicit both early and late adverse reactions in human
recipients [8,9]. Additionally, only a subset of the antibodies or antibody fragments present in these
antivenoms have a therapeutic value since the presence of non-toxic immunogens in the venoms
used for immunization may elicit therapeutically irrelevant antibodies in the immunized animal. This
was demonstrated by Pucca et al., who showed that only 1%–2.5% of antibodies in equine scorpion
antivenoms were able to neutralize important venom toxins [10]. Since scorpion and spider antivenoms
are derived from animal serum, individual differences in the immune responses of the production
animals may give rise to batch-to-batch variation [11]. Finally, due to the very minute amounts of
venom that can be extracted from scorpions and spiders, production of antisera against scorpion stings
and spider bites is dependent on a highly laborious venom collection process, where large numbers of
spiders and scorpions need to be milked (under microscope for spiders) in order to procure enough
venom for immunization [12]. These challenges warrant technological innovation, not only to obtain
safer and more effective antivenoms, but also to establish more sustainable productions processes that
are independent of both venoms and animals [9].
Table 1. Antivenoms on the market for treatment of spider bite envenomings.
Product Name Producer Country Type Spiders LinkReference
Funnel web spider




antivenom CSL Ltd. Australia Equine F(ab’)2
Latrodectus hasselti
(redback spider) [14]
Aracmyn Instituto Bioclon Mexico Equine F(ab’)2
Latrodectus mactans
(black widow spider),
Loxosceles spp. (recluse spiders)
[15]
Reclusmyn Instituto Bioclon Mexico Equine F(ab’)2 Loxosceles spp. (recluse spiders) [16]
Soro antiarachnidico Instituto Butantan Brazil Equine F(ab’)2







Biologics A.N.L.I.S. Argentina N/A
Latrodectus mactans




Salud, Perú Perú Equine IgG Loxosceles spp. (recluse spiders) [19]
Soro Antilatrodéctico Instituto Vital Brazil Brazil Equine F(ab’)2
Latrodectus mactans




Dohme International USA Equine IgG
Latrodectus mactans




Vaccine Producers South Africa N/A
Latrodectus indistinctus
(black button spider) [22]
Table 2. Antivenoms on the market for treatment of scorpion sting envenomings.
Product Name Producer Country Type Scorpions LinkReference
Suero















scorpion), Buthus occitanus (common
yellow scorpion), Androctonus crasicauda
(Arabian fat-tailed scorpion)
[25]
Toxins 2016, 8, 226 3 of 33
Table 2. Cont.

















quinquestriatus (Israeli yellow scorpion)
[27]
Alacramyn Instituto Bioclon Mexico Equine Fab Centruroides spp. (bark scorpions) [28]
Soro
antiarachnidico Instituto Butantan Brazil
Equine
F(ab’)2
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Androctonus australis (fat-tailed
scorpion), Buthus occitanus (common
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Vins Bioproducts Ltd. India Equine IgG


















India Equine IgG Buthus tamulus (red scorpion) [38]
This review presents the different biotechnological trends in the development of next generation
scorpion and spider antivenoms. Initially, focus will be directed towards the growing body of data on
spider and scorpion toxins and proteomes, which may be harnessed for developing either recombinant
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or synthetic antivenoms. A comprehensive overview of the use of immunization strategies is beyond
the scope of the paper, and can be found elsewhere [2]. However, the use of recombinant and synthetic
toxins obtained through the use of biotechnological approaches is discussed, as well as the potential
for including small molecules in future spider and scorpion antivenoms.
2. Current Knowledge of Toxins and Venom Proteomes
Both scorpion and spider venoms contain a range of different non-enzymatic and enzymatic
toxins [39,40]. The main toxic effects of scorpion venoms are in general derived from the inhibitory
actions of neurotoxins, whereas the effects of most described spider venoms originate from
both enzymatic toxins and neurotoxins. The most prominent components in spider venoms are
enzymatic sphingomyelinases, hyaluronidases, phospholipases, metalloproteases, serine proteases
and neurotoxins [39]. Scorpion venoms on the other hand mainly consist of neurotoxins (of which
particularly sodium and potassium channel targeting neurotoxins are prevalent) as well as enzymatic
proteins, such as hyaluronidases and phospholipases [3], protease inhibitors, and small molecules
such as histamine and serotonin [3].
Due to the very large number of spider and scorpion species, the toxin arsenal from these
venomous creatures is enormous and, to a large extent, unexplored. Based on the number of species
it is estimated that about 10 million spider toxins and about 100,000 scorpion toxins may exist [40].
These high theoretical numbers will naturally comprise orthologs with greater or lesser degree of
sequence identity. The scorpion Mesobuthus martensii (Manchurian scorpion), whose genome has
been sequenced, may express products from 116 neurotoxin genes, which mainly contain toxins from
four groups [41]. Based on a hierarchical clustering analysis, 17 clusters with very similar toxins
(closely resembling sub-family classification of the proteins) were identified within the 116 genes [41].
Taking these findings and the fact that different species can possess very similar toxins, an adjusted
rough estimate of the number of distinct scorpion toxin sub-families is in the order of 100–1000.
Given the much higher diversity within venomous spider families, the corresponding number of
distinct spider toxin sub-families is likely to be one or more orders of magnitude higher.
As of 13 June 2016, 1483 spider toxins and 949 scorpion toxins are annotated in the UniProtKB
database [42]. The vast majority of these toxins are derived from medically relevant species, possibly
leaving an enormous arsenal of bioactive venom components unexplored. Although much of the
exploration of spider and scorpion toxins has been triggered by an interest in using toxins for drug
discovery [43] and exploring crystal structures of receptors (see e.g., [44]), this pool of structural and
bioinformatics data serves as an excellent foundation for developing modern antivenoms, as several
important families of toxins are represented with a significant number of entries.
Our investigation shows that the majority (774 toxins) of annotated scorpion toxins (949 toxins)
can be found primarily within a single scorpion family (Buthidae) and belongs to a very limited number
of protein families (Figure 1B). The annotated toxins from spider venoms are more diverse both in
terms of protein family and taxonomic relationship (see Figure 1A). Four spider families, namely
Theraphosidae, Lycosidae, Sicariidae, and Ctenidae, are responsible for 1157 of the 1483 annotated
spider toxins. The high density of annotated scorpion toxins deriving from venoms of the Buthidae
family correlates with the fact that these scorpions are considered to be the most dangerous to human
health among all scorpion families [2]. In contrast, the multitude of families from which annotated
spider toxins originate may indicate that most studies on spider venoms have focused on finding novel
toxins that may be used for drug discovery, and not on critical toxins in an envenoming case.
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Figure 1. The t n protein families with the highest tries among the a no ated (A) spider
and (B) scorpion toxins in the UniProtKB database [42]. r s i ers 543 toxins do not belong to any of
the top ten protein families, while this number is 129 for scorpions. The bars are colored according to
the taxonomic family affiliation of each toxin entry.
Deeper investigation of the UniProtKB annotated toxin dataset reveals that only 100 species
of spiders and 77 scorpions contribute to the UniProtKB annotated toxin dataset. The majority of
these species contribute with five or fewer toxins, indicating that only the most abundant toxins
in t ese venoms have been characterized. The spider species with most annotated toxins are
Haplopelma hainanum (Chinese bird spider) with 292 toxin entries, Lycosa singoriensis (Wolf spider)
with 222 toxin entries, and Chilobrachys guangxiensis (Chinese earth tiger tarantula) with 104 toxin
entries. The corresponding top 3 contributors for scorpions are Mesobuthus martensii (Manchurian
scorpion) with 106 toxin entries (the only scorpion for which the genome is also available) [41],
Lychas mucronatus (Chinese swimming scorpion) with 89 toxin entries, and Leiurus quinquestriatus
(Egyptian scorpion) with 45 toxin entries. These numbers are likely to reflect the venom complexity
of the class of creatures in general. However, the presence of a large number of entries does not
necessarily indicate that the venom from a given species or the individual toxins are important from a
medical point of view.
The alternative and more holistic venomics approach, aiming at constructing overviews of
venom compositions on the protein family level, complements the studies of isolated toxins and
may help elucidate the medical importance of different venom components. Venomics studies help
generate knowledge of the abundance, toxicity, and sequence data for key toxin families, which
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may be harnessed for development of new cross-reacting antitoxins targeting shared features and
functionalities of the toxins [45,46]. As a result of the scarcity of venoms as well as previous limitations
on resolution and resolving power of separation and detection techniques, only a limited number of
venomics studies determining toxin identity and abundance have been carried out [40]. A number
of studies involving proteomics and/or transcriptomics have been performed for both spiders and
scorpions, respectively (Tables 3 and 4). As can be deduced from the tables, this number has been
growing with increasing speed in recent years, indicating a rising interest in toxin bioactivity and
venom compositions. For spiders, the main contributing species to these studies are found in the genus
Phoneutria (wandering spiders, Ctenidae family) with ten proteomics and transcriptomics studies (see
Table 3). For scorpions, the number of proteomics and transcriptomics studies (18) performed on
members of the genus Tityus from the Buthidae family dwarfs the number of studies performed on
any other genus, signifying scientific interest and indicating the importance of this genus to human
health [47] (see Table 4).
Table 3. Proteomics and transcriptomics studies performed on spider venoms.
Family Genus Species Prot. Tran. Reference
Agelenidae Agelena A. orientalis (funnel weaver spider)
‘
- [48]
Araneidae Araneus A. ventricosus (Chinese orb-weaving spider)
‘ ‘
[49]














P. nigriventer (Brazilian wandering spider)
‘ ‘
[53,54]






P. keyserlingi (Minas Gerais, Brazil)
‘
- [55]




P. reidyi (Para, Brazil)
‘
- [55]









H. infensa (Australian funnel-web spider)
‘ ‘
[40,56]




L. singoriensis (Chinese wolf spider) -
‘
[57]




D. fimbriatus (raft spider) -
‘
[59]
D. mizhoanus (fishing spider) -
‘
[60,61]
D. sulfurous (fishing spider) -
‘
[61]




L. gaucho (Brown spider)
‘
- [63]
L. intermedia (brown recluse spider)
‘ ‘
[64,65]
L. laeta (Chilean recluse spider) -
‘
[66]
Scytodidae Scytodes S. thoracica (spitting spider)
‘ ‘
[67]
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Table 3. Cont.
Family Genus Species Prot. Tran. Reference
Theraphosidae
Acanthoscurria A. paulensis (Brazilian giant black tarantula)
‘
- [68]
Chilobrachys C. jingzhao (Chinese earth tiger tarantula)
‘ ‘
[69,70]
Citharischius C. crawshayi (king baboon spider)
‘ ‘
[71]




H. hainanum (Chinese bird spider)
‘ ‘
[73–75]





L. geometricus (brown widow spider) -
‘
[81]
L. hesperus (Western black widow spider)
‘ ‘
[81,82]
L. tredecimguttatus (Mediterranean black widow)
‘ ‘
[83–85]
Steatoda S. grossa (cupboard spider) -
‘
[81]
Table 4. Proteomics and transcriptomics studies performed on scorpion venoms.
Family Genus Species Prot. Tran. Reference
Buthidae
Androctonus







Buthacus B. macrocentrus (Turkish scorpion)
‘
- [88]







H. conspersus (Sesriem scorpion) -
‘
[91]
H. judaicus (black scorpion) -
‘
[92]
Isometrus I. maculatus (lesser brown scorpion) -
‘
[93]
Leiurus L. quinquestriatus hebraeus (yellowscorpion)
‘
- [94]
Leiurus L. quinquestriatus quinquestriatus(deathstalker scorpion)
‘
- [94]
Lychas L. mucronatus (Chinese SwimmingScorpion) -
‘
[93]
Mesobuthus M. eupeus (lesser Asian scorpion)
‘ ‘
[95]




T. bahiensis (Brazilian scorpion)
‘ ‘
[94,99]
T. cambridgei (Amazonian scorpion)
‘
- [100]
T. costatus (Brazilian scorpion)
‘
- [101]
T. discrepans (Venezuelan scorpion)
‘
- [102]
T. pachyurus (Colombian scorpion)
‘
- [103]
T. serrulatus (Brazilian scorpion)
‘ ‘
[104–112]
T. stigmurus (Brazilian scorpion)
‘
- [94,113,114]
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H. petersii (Asian forest scorpion)
‘ ‘
[122]
Pandinus P. cavimanus (Tanzanian red clawedscorpion) -
‘
[123]
Scorpio S. maurus palmatus (chactoid scorpion)
‘ ‘
[124]
Urodacus U. yaschenkoi (inland robust scorpion)
‘ ‘
[125–127]
Verano-Braga and coworkers provide an excellent example of a venomics study performed on the
venom of Tityus serrulatus, in which they were able to detect the presence of 147 different proteins [111].
In terms of abundance, neurotoxins targeting sodium and potassium channels comprised 23% of the
venom, while enzymatic toxins were responsible for 32% of the protein content of the venom [111].
In another study, performed by Ma et al. on the venom of Heterometrus petersii, 22 protein families
were detected by a combined transcriptomics and proteomics approach [122], indicating high diversity
in scorpion venoms. In comparison, the venom of the African Citharischius crawshayi (King baboon
spider) was also analyzed by a venomics approach. Here, the venom was determined to be dominated
by peptides in the 3–6 kDa (58%) range, followed by lower molecular weight components in the
1–3 kDa (29%) range [71], suggesting that the effects of this venom are possibly derived from smaller
inhibitory toxins. A final example of a tour-de-force in proteomics is provided by Palagi and coworkers,
who investigated 18 venom samples from Australian funnel-web spiders (Hexathelidae family). They
detected an average of about 800 peptidic compounds in female spider venoms and approximately
400 peptidic compounds in male spider venoms with significant inter- and intra-species variation
in venom compositions [40], indicating that the high toxin diversity makes venoms very complex
drug targets.
In order to engage in specific toxin-directed antivenom development, a full overview of the
venom is warranted. However, in addition to estimations of quantitative venom proteomes, it
is highly beneficial to have information on toxin structures and estimates of toxin toxicities (e.g.,
LD50s), in order to have a full view on which toxins should be neutralized by novel antivenoms [128].
In 2016, Rodríguez-Rodríguez and coworkers employed approaches based on the Toxicity Score [46]
to determine which toxins are the medically most relevant in the venoms of selected Centruroides
scorpions [45]. This approach differentiated between medically relevant and medically irrelevant
toxins, and enabled the researchers to select key toxins for antitoxin development. Furthermore,
Rodríguez-Rodríguez et al. successfully employed structural analysis of complexes between toxins
and antitoxins to optimize binding affinity for their inhibitors [45]. Within the annotated toxin dataset
previously discussed, we find that 3D structures have been solved for a total of 63 spider toxins
and 93 scorpion toxins. Moreover, LD50s are known for 102 spider toxins and 86 scorpion toxins.
For 20 spider toxins and 27 scorpion toxins, both a 3D structure and an LD50 exist. The distribution of
these well characterized toxin entries between the taxonomic families are visualized in Figures 2 and 3.
Toxins 2016, 8, 226 9 of 33
Toxins 2016, 8, 226  9 of 33 
 
toxins and 93  scorpion  toxins. Moreover, LD50s are known  for 102  spider  toxins and 86  scorpion 






Figure 2. Number of toxins in each taxonomic family for which LD50s and/or three three-dimensional
structures have been reported in the UniProtKB database [42]. (A) Spider toxins; (B) Scorpion toxins.
The estimated >10 million scorpion toxins and spider toxins existing in nature [40] dwarf
the number of currently annotated toxins (2432) from these creatures. Hence, a more in depth
characterization would be beneficial in order to provide a better foundation for development of
novel antivenoms. Furthermore, the untapped pool of highly bioactive compounds constitutes
a treasure chest for toxin-derived drug discovery. Nevertheless, toxins from many of the medically
important species of both spiders and scorpions have already undergone thorough investigation.
The accumulated data on the structures, toxicities and abundances of these toxins represent a good
foundation for developing next generation antivenoms based on biotechnological approaches and
modern drug discovery techniques.
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Figure 3. Number of toxins in each protein family for which LD50s and/or three three-dimensional
structures have been reported in the UniProtKB database [42]. (A) Spider toxins; (B) Scorpion toxins.
3. Toxin Inhibition by Small Molecules
To the best of our knowledge, no small organic molecule has ever been tested for spider or
scorpion toxin neutralization in a clinical setting. Compared to snake venoms, limited research efforts
have focused on the discovery of small-molecule drugs targeting specific toxins in scorpion and spider
venoms. Only a handful of compounds has been reported to have neutralizing effects on scorpion or
spider venom components (Table 5).
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Table 5. Reported small molecules with inhibitory effect against scorpion and spider toxins.
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The first reported small molecule that was investigated in relation to inhibition of scorpion toxins
was heparin. Using turbidometric methods, heparin has been shown to inhibit hyaluronidases isolated
from various scorpion species, such as the Chinese red scorpion (Buthus martensi) [129] and the Indian
black scorpion (Palamneus gravimanus) [130]. In addition, heparin has been shown to inhibit the
hyaluronidase activity of venom from Heterometrus fulvipes, a species of the giant forest scorpions [140].
However, most studies on the effect of heparin on spider venoms demonstrate no inhibitory effect on
venom-induced necrosis [141]. In contrast, surgical excision or administration of effective antivenom
has been shown to be more efficacious [142]. However, it has been suggested that administration of
heparin alongside other treatments, such as steroids, hyperbaric oxygen treatments, experimental
antivenom, and/or surgical excision, may be beneficial in the treatment of bites from Loxosceles
spiders [143].
Neutralization studies on venom from the Brazilian yellow scorpion (Tityus serrulatus) with
Aristolochic acid demonstrate that this polyphenolic compound has the ability to decrease lethality
in mice [132]. Although focus in this study was on hyaluronidase enzymes, direct inhibition of
hyaluronidases was not tested. Other studies have shown, however, that Aristolochic acid has an
inhibitory effect on phospholipases A2 (PLA2s), which are found in scorpion venoms [120,132]. To date,
no inhibition studies with Aristolochic acid on PLA2s from spider venom have been reported, despite
the presence of PLA2s in arachnid venoms.
The bivalent metal ion chelators, EDTA and 1,10-phenanthroline, both function as metalloprotease
inhibitors (see Figure 4), and several studies indicate that both compounds are capable of neutralizing
spider and scorpion venoms by inhibiting various venom components [133,134]. EDTA has been
shown to inhibit PLA2 isolated from the scorpion H. fulvipes [140], as well as a range of different
proteinases isolated from the venom of the scorpion Isonietrus vittatus from Pakistan [135]. Moreover,
both EDTA and 1,10-phenatroline inhibit heminecrolysin, which is the enzyme responsible for the
main pathological effects in envenomation by the scorpion Hemiscorpius lepturus [133]. Heminecrolysin
is completely inhibited in vitro by EDTA at a concentration of 5 mM, and 50% inhibited by
1,10-phenantroline at a concentration of 2.5 mM [133].
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Apart  from  the  inhibition  of  individual venom  components, EDTA has  also been  shown  to 
inhibit  the proteolytic  activity of  the venom  from T. serrulatus on  fibrinogen  [136,139]. A  similar 
inhibition  of  proteolytic  activity  on  fibrinogen  has  also  been  observed  in  vitro  for  EDTA 
(concentration of 2 mM) and 1,10‐phenanthroline (concentration of 3 mM) on Loxosceles intermedia 
(Brown spider) venom  [134]. Finally, both EDTA and 1,10‐phenanthroline, at a concentration of 5 
mM  each,  have  been  shown  to  specifically  inhibit metalloproteases  isolated  from Hippasa partita 
venoms  [138], whilst  EDTA  (1 mM)  alone  has  proven  to  block metalloproteases  from  Parawixia 
bistriata (Araneidae genus) [137]. 
In  addition  to  the  examples  discussed  above,  a  number  of  other  molecules  have  shown 
neutralizing effects on toxins similar to those found in spider and scorpion venoms. As an example, 
Figure 4. echanism of inactivation of metalloproteases. The chelation agent EDTA chelates
metal ions and scavenges these from active metalloproteases leaving behind the inactive
metalloprotease apoprotein.
Apart from the inhibition of individual venom components, EDTA has also been shown to inhibit
the proteolytic activity of the venom from T. serrulatus on fibrinogen [136,139]. A similar inhibition of
proteolytic activity on fibrinogen has also been observed in vitro for EDTA (concentration of 2 mM)
and 1,10-phenanthroline (concentration of 3 mM) on Loxosceles intermedia (Brown spider) venom [134].
Finally, both EDTA and 1,10-phenanthroline, at a concentrati n of 5 mM each, have been shown to
specifically inhibit me alloproteases isolated from Hippasa partita venoms [138], whilst EDTA (1 mM)
alone h s proven to block metalloproteases from Parawixia bistriata (Araneidae genus) [137].
In addition to the examples disc s , a u ber of other molecules have shown
neutralizing effects on toxins similar to t se f i s ider and scorpion venoms. As an example,
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a recent study by El-kik et al. (2013) has indicated the ability of the poly-anionic compound suramin
to antagonize the cytotoxic and enzymatic effects of crude venom from the bee, Apis mellifera [144].
Interestingly, suramin has previously been indicated to inhibit the myotoxic actions of PLA2s in snake
venoms [128]. Therefore, it would not be surprising if suramin showed the same inhibitory effects on
scorpion and spider venoms containing these enzymes in abundance [39,145]. In a similar way, a large
number of other compounds that have shown neutralizing effect against snake venom toxins could
potentially also inhibit toxins from spiders and scorpions (particularly PLA2s) [128]. Nevertheless,
further experimental investigation is needed to determine such potential effects.
In conclusion, no small molecules targeting toxins from scorpion or spider venoms are in use in
the clinic. Although only few small molecules have been investigated, a range of compounds acting on
similar toxins from snakes has been discovered [128]. The potential of using such molecules in future
spider bite or scorpion envenoming therapy could be pursued with the aim of developing compounds
with improved stability and a large volume of distribution. Such properties may be of particular
benefit for targeting locally acting toxins in distal tissue, such as muscle tissue in arms and legs, which
are notoriously difficult to neutralize with traditional antivenoms. However, further research is needed
to explore the feasibility of this approach.
4. Research Efforts within Antibodies and Antibody Fragments
Modern biotechnological techniques for the generation, isolation, and production of monoclonal
antibodies (mAbs) or antibody fragments have recently been applied in the experimental development
of next generation antivenoms against scorpion stings and spider bites (see Table 6, Table 7, and
Table 8) [9]. The first reported neutralizing mAb in this field (mAb 4C1) was directed against the
venom of the Androctonus australis hector (Aah) scorpion [146], and it was generated using hybridoma
technology [147]. The toxicity of A. australis hector venom is derived from three small neurotoxins
belonging to two distinct structural and immunological groups (Group 1: Aah I and Aah III, and
Group 2: Aah II), and mAb 4C1 showed affinity for Aah II with a Kd of 0.8 nM [146]. Another antibody,
mAb 9C2, was generated against Aah I with a Kd of 0.15 nM, and it showed to be cross-reactive with
other toxins of the same group, having Kds of 1.5 nM for Aah III and 24 nM for Aah IV [148]. In mice,
1 mg of mAb 4C1 neutralizes 30,000 LD50s of Aah II, and 1 mg of mAb 9C2 neutralizes 1500 LD50s of
Aah I. When tested against whole venom, both mAbs were capable of neutralizing 40 LD50s [146,148].
Moreover, 1 mg of the mixture of 9C2 and 4C1 was able to neutralize 71 LD50 of the venom [148],
providing an excellent example of how selected mixtures of antibodies can be used to neutralize
selected medically relevant toxins, thereby abrogating the toxicity of whole venom [46].
Table 6. Reported work on murine monoclonal antibodies and antibody fragments against
spider toxins.
Name Target Type Author Year Ref.
LiMAb(7) Loxoscelesintermedia (recluse spider). mAb Alvarenga et al. 2003 [149]
FM1 Alpha-latrotoxin from Latrodectus sp.(black widow spiders). Fab Bugli et al. 2008 [150]
LiD1mAb16
Sphingomyelinases D from Loxosceles
intermedia, L. laeta and L. gaucho
(brown or recluse spiders).
mAb Dias-Lopes et al. 2014 [151]
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Table 7. Reported work on murine monoclonal antibodies and antibody fragments against
scorpion toxins.
Name Target Type Author Year Ref.
mAb 4C1 Aah I from Androctonus australis(fat-tailed scorpion) mAb Bahraoui et al. 1988 [146]
mAb BCF2
Cn2 from Centruroides noxius
(Mexican bark scorpion) mAb
Zamudio et al. 1992 [152,153]Licea et al. 1996
mAb 9C2 Aah II from Androctonus australis(fat-tailed scorpion) mAb
Clot-Faybesse
et al. 1999 [148]
scFv 4C1 Aah I from Androctonus australis(fat-tailed scorpion) scFv Mousli et al. 1999 [154]
mAbs BmK
AS-1
BmK AS-1 from Buthus martensii
karsch (Chinese scorpion) mAb Jia et al. 2000 [155]
scFv 9C2 Aah II from Androctonus australis(fat-tailed scorpion) scFv Devaux et al. 2001 [156]
chFab-BCF2 Cn2 from Centruroides noxius(Mexican bark scorpion) chFab Selisko et al. 2004 [157]
rFab 9C2 Aah I from Androctonus australis(fat-tailed scorpion) rFab Aubrey et al. 2004 [158]
Triple mutant
(G5 + B7)
Cn2 from Centruroides noxius
hoffmann
(Mexican bark scorpion)
scFvs Juárez-Gonzálezet al. 2005 [159]
mAbTs1
TsVII, TsIV and TsNTxP from
Tityus serrulatus
(brazilian yellow scorpion)
mAb Alvarenga et al. 2005 [160]
T94H6
Aah I and Aah II from
Androctonus australis
(fat-tailed scorpion)
Tandem-scFv Juste et al. 2007 [161]
Table 8. Reported work on non-murine recombinant antibodies and antibody fragments against
scorpion toxins.
Name Target Type Author Year Ref.
scFv 3F, scFv
6009F
Cn2 from Centruroides noxiushoffmann
(Mexican bark scorpion) Human scFv Riaño-Umbarila et al. 2005 [162]
NbAahI’22 AahI’ from Androctonus australis(Sahara scorpion) Camelid Nb Hmila et al. 2008 [163]
NbAahII10 AahII from Androctonus australis hector(Sahara scorpion) Camelid Nb Abderrazek et al. 2009 [164]
NbAah’F12 AahI from Androctonus australis(Sahara scorpion) Camelid Nb Hmila et al 2010 [165]
scFv 9004G Cn2 from Centruroides noxius hoffmann
and Css2 from Centruroides suffusus
suffusus (Mexican bark scorpions)
Human scFv Riaño-Umbarilaet al. 2011 [166]
scFv LR - - -
scFv 15e Ts1 or gamma-toxin from Tityusserrulatus (Brazilian yellow scorpion) Human scFv Amaro et al. 2011 [167]
NbF12-10 AahI and AahII from Androctonusaustralis (Sahara scorpion) Bispecific Nb Hmila et al. 2012 [168]
Db 9C2 +
Db4 C1
AahI and AahII from
Androctonus australis (Sahara scorpion)
Diabody
mixture Di Tommaso et al. 2012 [169]
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Table 8. Cont.
Name Target Type Author Year Ref.
Diabody D4,
scFv LER
Cn2 from Centruroides noxiushoffmann
(Mexican bark scorpion) Diabody
Rodríguez-Rodríguez
et al. 2012 [170]
Serrumab Ts1 and Ts2 from Tityus serrulatus(Brazilian yellow scorpion) Human scFv Pucca et al. 2012, 2014 [171,172]
scFv C1 Cn2 from Centruroides noxius hoffmann(Mexican bark scorpion) Human scFv Riaño-Umbarila et al. 2013 [173]
scFv 202F CII1 from Centruroides limpidus limpidus(Mexican bark scorpion) - - -
scFv RU1
Cn2 from Centruroides noxius hoffmann
(Mexican bark scorpion), and CII1 from
Centruroides limpidus limpidus
(Mexican bark scorpion)
Human scFv Riaño-Umbarila et al. 2016 [174]
scFv ER-5
Cn2 from Centruroides noxius Hoffmann
(Mexican bark scorpion), CII1 from
Centruroides limpidus limpidus
(Mexican bark scorpion), and Css2
from Centruroides suffuses suffuses
(Mexican bark scorpion)
Human scFv Rodríguez-Rodrígueset al. 2016 [45]
Similarly, the neutralizing mAb BCF2 was generated against toxins from scorpions of the
genus Centruroides [152]. The venoms of the three main species of Centruroides scorpions contain
toxins of high similarity (Css2 from C. sufusus suffusus, Cn2 from C. noxius, and CII1 and CII2 from
C. limpidus limpidus), and all bind to Na+ ion channels in excitable cells, modifying ion channel
activation and/or inactivation. BCF2 was directed against Cn2 from C. noxius, and 1 mg of this mAb
was capable of neutralizing 32 LD50s of the purified toxin and 28 LD50s of whole venom in mice [153].
Moreover, the antibody was tested for cross-reactivity against the venoms of C. limpidus limpidus,
C. limpidus tecomanus, C. limpidus acatlanesis, C. suffusus suffusus, C. infamatus infamatus, C. elegans and
T. serrulatus in ELISA plates. Despite a high degree of similarity between toxins from related scorpion
families, a clear strong signal was only detected against venom components of C. limpidus limpidus,
C. limpidus tecomanus and C. limpidus acatlanesis. Unfortunately, the neutralization capacity of BCF2
against venoms from these species was not tested in these studies.
The first reported mAb against a spider toxin was Li mAb(7), also obtained from a hybridoma cell
line [149]. Li mAb(7) was directed against venoms of spiders from the Loxosceles genus, commonly
known as recluse or brown spiders. The toxic effects of brown spiders are elicited by proteins of
the sphingomyelinase D (SMase D) family, which cause local effects at the bite site, such as edema,
local hemorrhage, and necrotic lesions, and systemic effects, such as hemolysis, thrombocytopenia,
and renal failure in some occasions. Li mAb(7) is capable of preventing dermonecrotic activity in
mice by targeting SMase D of L. intermedia. Nevertheless, the antibody did not show cross-reactivity
with venoms from other Loxosceles species [149]. Recently, a new murine mAb (LiD1mAb16) able to
recognize a highly conserved epitope in the SMases D of the three major medically important species
of Loxosceles spiders was generated by the same procedure. However, in vivo assays are only reported
for this mAb against the recombinant toxin and not whole venom [151].
The ability to clone and synthetically produce antibodies opened the possibility for replacing
hybridoma cell lines for heterologous expression systems and also exploring other antibody formats
with potentially optimized pharmacokinetic properties and enhanced shelf lives (Figure 5). As an
example, single-chain variable fragments (scFvs) based on the mAbs 9C2 and 4C1 were developed
and expressed in E. coli, and the resulting scFvs have Kds in the same nanomolar range as the intact
immunoglobulins [154,156]. In vivo, scFv4C1 displayed a protective capacity of 4000 LD50s of Aah
II per mg of scFv [154], and scFv 9C2 showed a protective capacity of 6600 LD50s of Aah I per mg of
the antibody fragment [156]. Due to their reduced size (Mw around 30 kDa), scFvs have been argued
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to have several potential advantages, such as increased diffusion rates, increased tissue penetrability,
increased biodistribution, and decreased immunogenicity. Since toxins are rapidly absorbed and
distributed, scFvs are potentially optimal molecules for neutralizing the effects of animal toxins [175].
In order to increase efficacy by exploiting avidity, scFvs can be joined together by a short linker,
creating bivalent molecules able to bind two different antigens simultaneously. The scFvs 4C1 and 9C2
were used as building blocks to design a tandem-scFv comprising the two scFvs fused together at the
genetic level (T94H6). This tandem-scFv showed Kds of 0.1 nM against Aah I and 1 nM against Aah
II. When tested in vivo, all mice co-injected with T94H6 and 3 LD50s of Aah I survived, whereas the
















mAb  BCF2 were  developed  using  error‐prone  PCR  to  introduce mutations  in  the CDR  regions. 







i 5. ti t ti f t ti f r t ti i t text. ( ) l
b fragments obtained after enzymatic leavage, us ally derived from hybridoma cell lines; (B)
Recombinant antibody molecules of human or murine origin, usually selected from synthetic libraries
by phage display selection; (C) Camelid heavy chain antibody (HCAb) and derived formats.
ajor breakthrough in antibody technology as achieved hen cCafferty et al. succeeded
in expressing the antibody V do ains on fila entous 13 phages, allo ing for rapid screening of
antibody genes via phage display selection (Figure 6) [176]. Using this technique, scFvs based on
the mAb BCF2 were developed using error-prone PCR to introduce mutations in the C R regions.
I proved variants were selected by phage display, and two of these, scFv G5 and scFv B7 (containing
two and one mutations, respectively), showed enhanced stability and a higher affinity for the toxin
(Kds of 0.43 nM and 0.71 nM, respectively) compared to the parental mAb. However, they still failed to
neutralize the toxin [159]. Subsequently, in order to overcome this weakness, the mutations contained
in G5 and B7 were introduced in a scFv triple mutant, which showed a Kd of 75 pM and increased
stability. In mice, 1 mg of the dimeric construct was able to neutralize 400 LD50s of Cn2 [159].
Toxins 2016, 8, 226 17 of 33Toxins 2016, 8, 226  17 of 33 
 
 
Figure  6.  Schematic  representation  of  a  directed  evolution  approach  by  phage  display  selection 
coupled  to mutagenesis  for discovery  of high  affinity  antibody  variants.  (A) Representation  of  a 
phage particle encoding and displaying scFv molecules on its surface. (B) Phage particles displaying 
a  library of  antibody  fragments  are panned  against  the  target  toxin  (1). Strongly binding phages 
remain bound  to  the  target, while non‐binding phages  are washed  away  (2). Binding phages  are 





One  of  the  scarce  examples  of  antibody  fragments  against  spider  toxins  is  the  Fragment 
antigen‐binding  (Fab) FM1, directed against α‐latrotoxin  from  the venom of  spiders of  the genus 




toxin  in  the  low  nM  range. When mice were  treated with  one LD100  of whole  venom,  20  μg  of 
purified FM1 prevented lethality in 100% of the cases [149]. 
Another  important  antibody  format  is  the  single  variable  domain,  consisting  of  only  the 
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Figure 6. Schematic representation of a directed evolution approach by phage display selection coupled
to mutagenesis for discovery of high affinity antibody variants. (A) Representation of a phage particle
encoding and displaying scFv molecules on its surface. (B) Phage particles displaying a library of
antibody fragments are panned against the target toxin (1). Strongly binding phages remain bound to
the target, while non-binding phages are washed away (2). Binding phages are eluted and (3) submitted
to mutagenesis, usually by error prone PCR or chain shuffling, with the intention of obtaining phage
particles with enhanced affinities towards the target (4). The obtained mutants are amplified in E. coli
and submitted to new panning rounds (5). After a few iterative cycles, the most strongly binding
phages are eluted, and their DNA is sequenced to reveal which antibody fragments bound most
strongly to the target.
f t r l f ti fr t i t i r t i i t r t
ti - i i ( ) , ir t i t ↵-l tr t i fr t f i r f t
ctro ectus, which are com only known as widow spiders [150]. The venom of widow spiders causes
potent neurotoxic effects by destabilizing presyna tic membranes of nerve terminals, which leads to
C 2+ influx and massive releas of neurotransmitters. FM1 was isolated from a phage display librar
constru ted with the antibody repertoi of immunized mice and showed an affinity for the toxin in
the low nM range. When mice w re treated with one LD100 of whole venom, 20 µg of purified FM1
revented lethality i 100% of the cases [150].
t important antibody format is the single variable domain, consisting of o ly the a tibody
heavy chain (VHH). These VHH fragments (popularly termed “nanobo ies”, abbreviated “Nb”) can
be isolated from th immune syste of cam lids and sharks [128,177]. With a molecular weight of
15 kDa, nanobodies represent the smallest, intact, n tural a tigen-binding fragments known, nd they
have the beneficial properties of good stability (ex viv ), high level of expression in microbial systems,
high solubility, good specificity, and high affinity for their respective antigens [178,179]. Although
nanobodies are rapidly cleared from the blood [180], their low m lecular weight may be advantageous
for reaching the toxins having been distributed into orga s and deep tissue upon scorpion sting
Toxins 2016, 8, 226 18 of 33
or spider bite. Moreover, nanobody-toxin complexes remain below the renal cut-off (60 kDa), thus
enabling their excretion by renal clearance in envenomed victims [168].
In 2009, a large VHH library from the lymphocytes of an immunized dromedary was generated
and screened by phage display selection against Aah II [164]. One particular nanobody (NbAahII10)
showed an extraordinarily high neutralizing capacity (37,000 LD50s of Aah II per mg of nanobody).
This represents a considerable accomplishment of paramount importance in the field of antibody
fragments [164]. In 2010, the same group selected the nanobody NbAah’F12 against Aah I by a similar
procedure, and this nanobody provided full protection in mice challenged with 100 LD50s of the
toxin [165]. In the same study, a bispecific nanobody of 29 kDa directed against Aah I/Aah II,
NbF12-10, was reported to neutralize 5 LD50s of whole venom and restoring the heart rate dysfunction
induced by Aah envenoming in mice [165].
Thus far, none of the aforementioned mAbs or antibody fragments have been of human origin.
Therefore, they come with a risk of eliciting undesired adverse reactions in human recipients.
An attempt to overcome this issue is exemplified by the development of chimeric human antibody
constructs, which are obtained by joining the variable region genes of an antibody molecule produced
from a myeloma cell line with human immunoglobulin constant region genes [181]. The non-human
regions of the resulting mAb are reduced while the pharmacokinetic properties remain unaffected.
The chimeric Fab, chFab-BCF2, comprises the variable regions of the murine mAb BCF2 and human
constant regions. In vitro, chFab-BCF2 showed an IC50 of 3 nM, which is in the same range as the IC50
of the whole mAb. When tested in mice, 3.75 µg of the chimeric construct neutralized one LD50 of the
toxin, and 6.25 µg neutralized one LD50 of whole venom [157].
Humanization procedures have been developed for murine mAbs and its diverse formats [182,183],
but humanization is a complex procedure, often accompanied by a decrease in affinity and neutralizing
capacity of the molecules [182]. Therefore, mAbs should ideally be of human origin to be included in
antivenoms. In the last decade, a few mAbs directed against scorpion toxins have been isolated from
human phage display libraries (see Table 8). However, no mAbs of human origin against spider toxins
have yet been reported.
In 2005, Riaño-Umbarila et al. isolated scFvs 3F and C1, two recombinant human antibody
fragments capable of neutralizing the toxic effects of the toxin Cn2 and whole venom of C. noxius [162].
In the same study, scFv 3F was matured by three cycles of directed evolution to obtain scFv 6009F,
with a Kd of 0.41 nM for Cn2. In vivo, scFv 6009F neutralized 2 LD50s of the Cn2 toxin when molar
ratios of 1:10 and 1:2 toxin-to-antibody fragment were injected [162]. Some years later, the same
group showed that scFv 6009F was cross-reactive against toxins Css2, Cn3, and Css4, suggesting that
the fragment was able to recognize a conserved epitope important for neutralizing the toxin [166].
Subsequently, additional maturation cycles were performed with the parental scFv against the toxin
Css2 from C. suffusus, leading to the isolation of scFv 9004G. scFv 9004G showed a Kd of 0.81 nM for
Css2, and was able to provide protection in mice challenged with 1:10 molar ratio of toxin-to-antibody
fragment [166]. With the aim of obtaining a molecule capable of simultaneously neutralizing Cn2
and Css2, the important mutations for toxin recognition were identified in both scFv 6009F and scFv
9004G, and the best properties were merged to generate a third scFv, named LR. scFv LR had a Kd
value of 0.02 nM for Cn2 and 0.09 nM for Css2, and showed excellent stability in vitro when submitted
to strong denaturing conditions. In vivo, all mice survived when treated with 1:10 molar ratios of
toxin-to-antibody fragment for Cn2 or Css2, and the antibody fragment was able to provide full
protection when 3 LD50s of whole venom of C. suffusus or C. noxius were administered at a molar
ratio of 1:3 [166]. scFv LR and scFv 6009F were both further optimized in subsequent studies through
directed evolution and further biopanning of Diabody 6009F (a dimerized version of scFv 6009F). This
led to the identification of a new mutation (E43G), which provided increased functional stability and
neutralization capacity for the optimized versions, Diabody D4 and scFv LER, compared to Diabody
6009F and scFv LR [170]. An additional scFv, named 202F, was derived from scFv C1 after 3 cycles
of directed evolution against toxin CII1 from C. limpidus, and it neutralized one LD50 of both Cn2
Toxins 2016, 8, 226 19 of 33
and CII1 toxins [173]. With the aim of improving the neutralization capacity of scFv 202F, the same
group generated a new antibody fragment, named scFv RU1, through incorporation of two different
mutations. The scFv neutralized one LD50 of CII1 toxin, two LD50s of Cn2 toxin, and 3 LD50s of
fresh whole C. noxius venom [174]. To expand the neutralization capacity toward additional scorpion
toxins, scFv RU1 was subjected to in vitro maturation followed by phage display selection in order
to identify mutations yielding cross-reactive scFvs with uncompromised affinity towards the toxins.
By employing this approach and combining different identified mutations, the scFv ER-5 was obtained.
scFv ER-5 recognized toxins Css2, Css4, Cn2, and CII1, and neutralized one LD50 of both Cn2 and
CII1 toxins, and two LD50s of whole C. suffusus venom [45], which demonstrates the power of phage
display technology coupled to semi-rational approaches for affinity optimization.
In the case of T. serrulatus, a scorpion responsible for most of the severe cases of scorpion
envenomation in Brazil, a neutralizing scFv (scFv 15e) was isolated by phage display selection from
a human library. The most toxic components of the venom of T. serrulatus are neurotoxins that exert
their effect by binding to voltage-gated Na+ ion channels. Neurotoxins are classified into ↵-toxins (Ts3
and Ts5) and  -toxins (Ts1 and Ts2). scFv 15e is directed against Ts1, the main toxic component of T.
serrulatus venom, and also recognizes toxins from T. cambridgei and T. packyurus, two related scorpions
from the same genus [167]. The neutralization capacity of scFv 15e against Ts1 was very limited, as 12
out of 16 mice challenged with one LD50 of the toxin survived [167]. Currently, optimized variants of
scFv 15e are being obtained using a directed evolution approach coupled to phage display with the
aim of enhancing its neutralization capacity, but successful results have yet to be reported [167].
Another relevant example of a human scFv is Serrumab, which is directed against toxins in the
venom of T. serrulatus. Serrumab was isolated after four rounds of phage display selection from a
synthetic human library against whole venom of the scorpion. In vitro, Serrumab neutralized the
toxins Ts1 and Ts2 ( -toxins), but undetectable or low reactivity was reported against Ts3 and Ts5
(↵-toxins). In vivo, the increase in the plasma levels of urea, creatinine, and neutrophil recruitment
associated to envenomation was not observed in mice treated with Serrumab, in contrast to animals
that received venom alone [171]. Furthermore, Serrumab showed cross-reactivity against Css II from
C. suffusus suffusus and Lqh III from L. quinquestriatus hebraeus. Nevertheless, in vivo assays using
isolated toxins have not yet been performed due to the difficulty of obtaining sufficient quantities of
toxins [172].
The highlighted examples above display some trends in the development effort within spider
and scorpion envenomation therapies. Increasing interest and efforts exist within the generation of
recombinant, human antibody fragments using phage display technology [9]. The benefits of using
phage display technology include the possibility of modifying the antibodies or fragments by genetic
engineering techniques or affinity maturation by directed evolution. In addition, manufacturing
processes for antibodies and antibody fragments have undergone a major development in the past
30 years with production cost of antibodies having decreased significantly [184,185]. Developments in
both antibody technologies and manufacturing technology may indeed be the key to enable production
and distribution of antibody-based envenomation therapies to poor, rural parts of the tropical world,
where the cost of medicine may be an inhibiting factor for treatment. In comparison to scorpions,
the field of antibody-based antitoxins against spider toxins is less developed. Reasons for this may
include the minor severity or lower prevalence of spider bites in most of the world, and the difficulty
of obtaining sufficient quantities of medically important spider venoms.
5. Next Generation Immunization Strategies
A complementary approach to using recombinant antibodies or antibody fragments is the use
of recombinant toxins or synthetic peptides for animal immunization procedures (Figure 7). Such
approaches may provide a path to obtaining antivenoms with higher titers of antibodies against the
relevant toxins and low titers against medically unimportant venom components. Within spider and
scorpion antivenoms, efforts have been made with both strategies (Tables 9 and 10). However, in
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Figure 7. Schematic representation of the us i ic epitopes for i munization. A peptide
contai ing the most reactive pitope seque ( ) f selected toxin(s) is constructed and used for
immunization of mice. In a successful i unization, the antibodies raised will not only target the
peptide, but also the parent toxin(s).
Table 9. Reported work on next generation immunization strategies for spider antivenoms.
Immunization Strategy Target Author Year Ref.
Recombinant toxin A dermonecrotic t xin fromLoxoscelesintermedia (reclus spider) Araujo et al. 2003 [186]
Synthet c epitope A dermonecrotic toxin fromLoxoscelesintermedia (reclus spider) Felicori et al. 2009 [187]
Synthetic toxin Robustoxin from Atrax robustus (Sydneyfunnel-web spider) Comis et al. 2009 [188]
Recombinant toxin A dermonecrotic toxin fromLoxoscelesintermedia (reclus spider) Mendes et al. 2013 [189]
Table 10. Reported work on next generation immunization strategies for scorpion antivenoms.
Immunization
Strategy Target Author Year Ref.
Synthetic epitope AaH2 from Androctonus australis(Sahara scorpion) Bahroui et al. 1986 [163]
Synthetic epitope Cn2 from Centruroides noxius(Mexican bark scorpion)
Calderon-Aranda
et al. 1995 [191]
Recombinant toxin BotXIV from Buthus occitanus tunetanus(common European scorpion)
Bouhaouala-Zahar
et al. 1996 [192]
Synthetic epitope AaH2 from Androctonus australis hector(Sahara scorpion) Devaux et al. 1997 [193]
Synthetic epitope Cn2 from Centruroides noxius Hoffmann(Mexican bark scorpion)
Calderon-Aranda
et al. 1999 [194]
Recombinant toxin TsNTxP from Tityus serrulatus(Brazilian yellow scorpion) Guatimosim et al. 2000 [195]
Recombinant toxin AaH1, AaH2 and AaH3 fromAndroctonus australis (Sahara scorpion) Legros et al. 2001 [196]
Recombinant toxin Bot III from Buthus occitanus tunetanus(common European scorpion) Benkhadir et al. 2001 [197]
Synthetic epitope TsNTxP and TsIV from Tityus serrulatus(Brazilian yellow scorpion) Alvarenga et al. 2002 [198]
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Table 10. Cont.
Immunization
Strategy Target Author Year Ref.
Recombinant toxin Cn5 from Centruroides noxius Hoffmann(Mexican bark scorpion) Garcia et al. 2003 [199]
Synthetic epitope Birtoxin from Parabuthus transvaalicus(South African fat-tail Scorpion) Inceoglu et al. 2006 [200]
Recombinant toxin Ts1 from Tityus serrulatus(Brazilian yellow scorpion) Mendes et al. 2008 [201]
Recombinant toxin PG8 from Parabuthus granulatus(granulated thick-tailed scorpion) García-Gómez et al. 2009 [202]
Recombinant toxin Css2 from Centruroides suffusus suffusus(Mexican bark scorpion)
Hernández-Salgado
et al. 2009 [203]
Synthetic epitope TsNTxP from Tityus serrulatus(Brazilian yellow scorpion) Duarte et al. 2010 [204]
Within scorpion antisera, the first use of a synthetic peptide for immunization was reported in
1986, where Bahraoui et al. conjugated a nine amino acid long epitope from the AaH2 toxin from
A. australis to albumin. The anti-peptide serum raised in rabbits against the albumin-AaH2 epitope
was able to neutralize the natural toxin, but no results against the crude venom were reported [190].
In 1999, Calderon-Aranda et al. engineered a peptide from the Centruroides noxiusCn2 toxin, containing
continuous and discontinuous epitopes, by linking the N- and C-terminus of the resulting peptide by
a disulfide bridge. The anti-peptide antiserum produced in rabbits could neutralize 39.5 LD50 of Cn2
per mL of serum [194].
In 2000, Guatimosim et al. reported the use of a non-toxic, recombinantly expressed version
of the immunogenic protein (TsNTxP) from T. serrulatus venom for immunization of rabbits [195].
1 mL of the raised antiserum was able to protect rabbits injected with 20 LD50 of the whole venom.
The TsNTxP-derived protein was produced as a fusion protein with a maltose-binding protein, in
order to avoid degradation by the molecular machinery of E. coli cells [195].
In 2004, Machado de Ávila et al. prepared an immunogen consisting of the most toxic fraction
(TstFG50) of the T. serrulatus venom conjugated to bovine serum albumin (BSA). Mice immunized
with TstFG50-BSA showed full protection when challenged with 2 LD50s of TstFG50 [205]. In a more
recent study, a SPOT mapping method was used to identify discontinuous epitopes of TsNTxP, and
the most reactive peptide sequences were combined on a linear strand (GREGYPADGGGLPDSVKI).
This linear strand was used for immunization of mice, which were fully protected when challenged
with 1.75 LD100s of T. serrulatuswhole venom [204].
Also using the SPOTmethod, Alvarenga et al. mapped three antigenic regions on TsNTxP and one
epitope on TsIV, the latter of which is the most lethal venom component of T. serrulatus belonging to the
alpha-type toxin family. Antibodies from antiserum raised against these four peptides were conjugated
to keyhole limpet hemocyanin (KLH), and 1 mL of the anti-peptide serum was able to neutralize
13.5 LD50s of whole venom from T. serrulatus in vitro. Apart from showing high reactivity against the
crude venom of T. serrulatus, the anti-peptide antibodies in the serum bound moderately to the venoms
of T. bahiensis, T. cambridgei, T. stigmurus, and venoms from the Centruroides genus. Therefore, this
study showed that antibodies generated against peptides derived from the toxins of one scorpion can
cross-react and neutralize venoms from different scorpion species, providing an alternative strategy
for the preparation of polyspecific scorpion antivenoms [198].
Within spider antivenoms, the use of both recombinant and synthetic toxins for immunization
has been explored. In 2003, Araujo et al. constructed a recombinant fusion protein between a protein
homologous to a dermonecrotic toxin from L. intermedia and beta-galactosidase. The protein was
expressed in E. coli, and subsequently used as antigen for the immunization of rabbits and mice.
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The immunized rabbits showed prolonged in vivo protection against the whole venom, and the mice
achieved full protection against 2.5 LD50s of whole venom [186]. In 2013, Mendes et al. constructed
a chimeric protein containing three epitopes of LiD1, a dermonecrotic toxin present in the venom of
L. intermedia. When rabbits were immunized with the recombinant chimeric protein (rCpLi), they were
able to elicit a protective immune response against whole venom from both L. intermedia and L. gaucho,
comparable to rabbits immunized with the natural toxin [189].
In 2009, Comis et al. chemically synthesized the 42 amino acid long robustoxin from the venom of
Atrax robustus, and used this toxin for immunization ofMacaca fascicularismonkeys. The toxin was
prepared without establishing the disulfide bridges that are essential for toxicity, and co-polymerizing
the toxin with keyhole limpet haemocyanin. Immunized monkeys survived when challenged with a
lethal dose of the crude venom, having a full recovery with only minor symptoms of envenoming [188].
Although the use of recombinant toxins or synthetic peptides for immunization of animals does
not radically change the nature of antivenoms, several potential benefits may be reaped. First of all,
it excludes the need for laborious venom extraction, where either large numbers of spiders need to
be farmed or caught and milked under a microscope, or where electrical stimulation methods are
needed for collection of scorpion venoms [12]. Independence of venoms may not only help reduce
cost, but it may also yield a much less hazardous production process, remove the risk and impact of
potential diseases among spiders or scorpions used for venom collection, and remove the effect of
individual venom variability among specimens used for venom collection. Moreover, the possibility of
only using the medically relevant toxins or peptide epitopes for immunization may yield better titers
of therapeutically active antibodies which, in turn, may lead to more potent antivenoms. In addition to
higher efficacy, more potent antivenoms may elicit fewer side effects, since less antivenom is needed to
treat the envenomed victim [128]. However, limitations to these strategies include the inability of some
heterologous expression organisms to produce recombinant toxins with correct disulphide bonding
and protein structure, and the fact that linear peptides may not always yield therapeutically active
antibodies when used for immunization [2].
6. Future Perspectives
The array of analytical tools for analysis of venoms and toxins may possibly lay the foundation
for introducing new innovations into the field of scorpion and spider antivenoms. Given that less
medically relevant toxins in scorpion and spider venoms are essential to neutralize compared to snake
venoms [9], and given the more laborious venom extraction procedures required for current scorpion
and spider antivenom production, introduction of recombinant production methods for oligoclonal
human antibodies or fragments thereof may indeed be a promising possibility, which is likely to be
both feasible, cost-competitive [185], and which may yield more efficacious serum-free antivenoms
with better safety profiles [11,128]. Coupled to powerful discovery platforms, such as phage display
selection or the use of humanized animals, recombinant expression technologies could revolutionize
the field of antivenoms by delivering safer, more efficacious therapies that are affordable for the
healthcare systems of the developing world. However, in order for such a technological breakthrough
to happen, more research efforts need to be directed towards scorpion and spider venomics, antitoxin
discovery, and novel expression technologies.
Hopefully, the future may generate novel therapies that can help combat the neglected area of
scorpion and spider envenomings, causing much mortality and morbidity among people living the
regions affected by this burden.
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